Abstract
Background/Aim: The evidence on the efficacy of somatostatin analogues in the treatment of hepatocellular carcinoma (HCC) in humans is conflicting. A variety of human tumors demonstrate somatostatin receptors. All subtypes bind human somatostatin with high affinity, while somatostatin analogues bind with high affinity to somatostatin receptor subtype 2 (sst2). We investigated the sst2 expression in HCC and examined whether HCCs expressing sst2 are a distinct subgroup. Patients and Methods: Forty-five human HCCs were tested for sst2 expression and biological alterations. The proliferative capacity was determined with Ki67 immunostaining and the DNA ploidy status was measured by fluorescent in situ hybridization with a chromosome 1-specific repetitive DNA probe. Expression of tumor suppressor genes (p16, p53 and Rb1) was measured by immunohistochemistry. Results: sst2 expression was detected in 30 tumors (67%). No correlation existed between sst2 expression and the immunoprofiles of the tumor suppressor genes, aneuploidy, proliferation, age, gender, α-fetoprotein levels, tumor size, tumor grade and underlying liver disease. Conclusion: In 67% of the patients with HCC, sst2 could be detected in the tumor. No clinical, pathological or biological characteristics were specific for sst2-positive tumors.
References
1.
El-Serag H, Davilla JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003;139:817–823.
2.
Verhoef C, Visser O, de Man RA, de Wilt JHW, Ijzermans JNM, Janssen-Heijnen MLGl: HCC in the Netherlands: incidence treatment and survival patterns. EJC 2004;40:1530–1538.
3.
Schwartz JD, Beutler AS: Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials. II. systemic and local non-embolization-based therapies in unresectable and advanced hepatocellular carcinoma. Anticancer Drugs 2004;15:439–452.
4.
Yuen MF, Poon RT, Lai CL, et al: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2003;36:687–691.
5.
Rabe C, Pilz T, Allgaier, et al: Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol 2002;40:395–400.
6.
Raderer M, Hejna MH, Muller C, et al: Treatment of hepatocellular cancer with the long acting somatostatin analoglanreotide in vitro and in vivo. Int J Oncol 2000;16:1197–1201.
7.
Dimitrouloupoulos D, Xinopoulos D, Tsamakidis K, et al: The role of sandostatin LAR in treating patients with advanced hepatocellular cancer. Hepatogastroenterology 2002;49:1245–1250.
8.
Samonakis DN, Moschandreas J, Arnaoutis T, et al: Treatment of hepatocellular carcinoma with long acting somatostatin analogues. Oncol Rep 2002;9:903–907.
9.
Gibson JB, Sobin LH: Histological typing of tumours of the liver, biliary tract and pancreas; in International Histological Classification of Tumours. Geneva, World Health Organisation, 1978.
10.
Edmondson HA, Steiner PE: Primary carcinoma of the liver. A study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503.
11.
Alers JC, Van Dekken H: Interphase cytogenetic analysis of solid tumors by non-isotopic DNA in situ hybridization. Progr Histochem 1996;31:1–137.
12.
Van Dekken, Wink J, Alers JC, de Man RA, Ijzermans JN, Zondervan PE: Genetic evaluation of the dysplasia-carcinoma sequence in chronic viral liver disease: a detailed analysis of two cases and a review of the literature. Acta Histochem 2003:105:29–41.
13.
Van Dekken H, Verhoef C, Wink J, van Marion R, Vissers KJ, Hop WC, de Man RA, Ijzermans JN, van Eijck CHJ, Zondervan PE: Cell biological evaluation of liver cell carcinoma, dysplasia and adenoma by tissue micro-array analysis. Acta Histochem 2005:107:161–171.
14.
Hofland L, et al: Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors. J Clin Endocrinol Metab 1999;84:775–780.
15.
Korner M, et al: Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 2005;29:1642–1651.
16.
Schally AV: Oncological applications of somatostatin analogues. Cancer Res 1988;48:6977–6985.
17.
Lamberts SW, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991;12:450–482.
18.
Weckbecker G, Raulf F, Stolz B, Bruns C: Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993;60:245–264.
19.
Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442–447.
20.
Allgaier HP, Becker G, Olschewski M, et al: Octreotide treatment in patients with advanced hepatocellular carcinoma: first results of the randomized placebo-controlled double blind Hector trial. Hepatology 2003;38:760A.
21.
Bläker M, Schmitz M, Gocht A, et al: Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas. J Hepatol 2004;41:112–118.
22.
Reubi JC, Zimmerman A, Jonas S, Waser B, Neuhaus P, Laederach U, Wiedenmann B: Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999;45:766–774.
23.
Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S: Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005;92:175–186.
24.
Reynaert H, Rombouts K, Vandermonde A, et al: Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma. Gut 2004;53:1180–1189.
25.
Reubi JC: Octreotide and nonendocrine tumors. Basic knowledge and therapeutic potential; in Lomax P, Scarpignato C, Vessel E (eds): Octreotide from Basic Science to Clinical Medicine. Basel, Karger, 1996, pp 246–269.
26.
Reubi JC, Laissue J, Krenning E, Lamberts SW: Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992;43:27–35.
27.
Zhang CY, Yokogoshi Y, Yoshimoto K, Fujinaka Y, Matsumoto K, Saito S: Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 1995;210:805–815.
28.
Hsu HC, Tseng HJ, Lai PL, et al: Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumour growth and invasiveness. Cancer Res 1993;53:4691–4694.
29.
Hsu HC, Peng SY, Lai PL, et al: Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int J Oncol 1994;4:1341–1347.
30.
Peng SY, Chen WJ, Lai PL, et al: High α-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and β-catenin. Int J Cancer 2004;112:44–50.
31.
Qin LX, Tang ZY, Ma ZC, et al: p53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection. World J Gastroenterol 2002;8:459–463.
32.
Sherr CJ: Cancer cell cycles. Science 1996;274:1672–1677.
33.
Baek MJ, Piao Z, Kim NG, et al: P16 is a major inactivation target in hepatocellular carcinoma. Cancer 2000;89:60–68.
34.
Matsuda Y, Ichida T, Genda T, et al: Loss of p16 contributes to p27 sequestration by cyclin D1-cyclin-dependent kinase 4 complexes and poor prognosis in hepatocellular carcinoma. Clin Cancer Res 2003;9:3389–3396.
35.
Edamoto Y, Hara A, Biernat W, et al: Alterations of RB1, p53 and Wnt pathways in hepatocellulular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. Int J Cancer 2003;106:334–341.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
